None listed
Conditions
Interventions
Intervention1: Test Product 1-BM: Equivalent to 25 g of available carbohydrate, served with 200 ml of water to the Subject once in the Study
Intervention2: Test Product 2-BMM: Equivalent to 25 g of av
Sponsors
CLINISYD Research Global Solutions Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Healthy adults (based on medical history and screening tests) in the age group of 18 and 45 years – subjects 2.Fasting blood glucose levels less than or equal to 100mg/dL. 3.Glycosylated Hemoglobin (HbA1c) less than or equal to 100mg/dL. 5.6 as per American Diabetes Association (ADA) 4.BMI should be between 18.5 to 25 kg/m2 5.HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) less than or equal to 100mg/dL.2.5 as per American Diabetes Association (ADA) 6.Lipid profile (Total cholesterol) within normal range as applicable 7.Must be willing to give written informed consent and comply with the study procedures. 8.Subject’s complete blood count parameters to be within clinically acceptable range by Investigator. 9.Willing to abstain from other functional foods or supplements during the study 10.Not currently on any medication or supplement affecting glucose, lipid, or weight metabolism
Exclusion criteria
Exclusion criteria: 1.Subjects particularly on any special diet 2.Subjects suffering from any systemic disorders (diabetes mellitus, cardiovascular, renal, pulmonary, endocrine, or neurological disorders, ulcers, dermatologic disorders, autoimmune diseases) or severe food allergies; an active infectious disease (HBV, HCV, HIV) 3.current diagnosis or a history of relevant depressive episodes or of panic attacks, psychosis, bipolar or eating disorders 4.Patient having participated in any other clinical trial within one month prior to screening 5.Current use of Use of medications or supplements that affect outcomes 6.Allergy or intolerance to millets, cereals, fenugreek, cinnamon, moringa, or any study ingredients 7.Any other medical condition or circumstance that, in the investigator’s judgment, would make participation unsafe.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess glycemic index using blood sugar levelsTimepoint: To assess glycemic index using blood sugar levels of test products measured at fixed intervals (-5, 15, 30, 45, 60, 90 and 120 min | — |
Secondary
| Measure | Time frame |
|---|---|
| Glycaemic Index(GI) of the test product assessing C-peptide levelsTimepoint: at -5min and after 120 min | — |
Countries
India
Contacts
Public ContactDr Madhusudan C
NRR Hospital
Outcome results
None listed